In vitro inhibition of multiple cytochrome P450 isoforms by xanthone derivatives from mangosteen extract

Drug Metabolism and Disposition

Volumn 37, Issue 9, 2009, Pages 1848-1855

  Foti, Robert S ^a   Pearson, Josh T ^a   Rock, Dan A ^a   Wahlstrom, Jan L ^a   Wienkers, Larry C ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ISOMANGOSTIN; 8 DESOXYGARTANIN; 9 HYDROXYCALABAXANTHONE; ALPHA MANGOSTIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GARTANIN; MANGOSTEEN EXTRACT; MANGOSTIN; PLANT EXTRACT; ROSIGLITAZONE; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PERICARP; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GARCINIA MANGOSTANA; HUMANS; ISOENZYMES; KINETICS; MASS SPECTROMETRY; MICROSOMES, LIVER; NADP; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; PLANT EXTRACTS; XANTHONES;

GARCINIA MANGOSTANA;

EID: 70349100119     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028043     Document Type: Article

References (37)

1. Balunas MJ, Su B, Brueggemeier RW, and Kinghorn AD (2008) Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod 71:1161-1166.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832. (Pubitemid 36759050)
3. Blumenthal M, Ferrier GKL, and Cavaliere C (2006) Total sales of herbal supplements in the United States show steady growth. HerbalGram 71:64-66.
4. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, and Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 55:2325-2333.
5. Burns M (1999) Management of narrow therapeutic index drugs. J Thromb Thrombolysis 7:137-143. (Pubitemid 29224993)
6. Chang TK, Chen J, and Benetton SA (2002) In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 30:378-384. (Pubitemid 34263821)
7. Chen SX, Wan M, and Loh BN (1996) Active constituents against HIV-1 protease from Garcinia mangostana. Planta Med 62:381-382. (Pubitemid 26272530)
8. Craig WJ (1999) Health promoting properties of common herbs. Am J Clin Nutr 70:491S-499S.
9. Di Matteo V and Esposito E (2003) Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2:95-107.
10. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, and Choudri S (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4:176-184. (Pubitemid 34305609)
11. Foti RS and Wahlstrom JL (2008) The role of dietary supplements in cytochrome P450-mediated drug interactions. Lat Am Bull Carib Med Arom Plants 7:66-84.
12. Galetin A, Ito K, Hallifax D, and Houston JB (2005) CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 314:180-190. (Pubitemid 41058254)
13. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, and Ang CY (2005a) Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:522-539. (Pubitemid 41003065)
14. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, and Shah A (2005b) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-426.
15. He N and Edeki T (2004) The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11:206-212.
16. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304. (Pubitemid 46174829)
17. Ji X, Avula B, and Khan IA (2007) Quantitative and qualitative determination of six xanthones in Garcinia mangostana L. by LC-PDA and LC-ESI-MS. J Pharm Biomed Anal 43:1270-1276. (Pubitemid 46282364)
18. Jung HA, Su BN, Keller WJ, Mehta RG, and Kinghorn AD (2006) Antioxidant xanthones from the pericarp of Garcinia mangostana (Mangosteen). J Agric Food Chem 54:2077-2082.
19. Kosem N, Youn-Hee H, and Moongkarndi P (2007) Antioxidant and cytoprotective activities of methanolic extract from Garcinia mangostana hulls. Sci Asia 33:283-292.
20. Liu Y, Zhang JW, Li W, Ma H, Sun J, Deng MC, and Yang L (2006) Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 91:356-364. (Pubitemid 43827288)
21. Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS, and Chavin KD (2003) Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 74:536-542. (Pubitemid 37521997)
22. Modarai M, Gertsch J, Suter A, Heinrich M, and Kortenkamp A (2007) Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 59:567-573. (Pubitemid 47051131)
23. Moongkarndi P, Kosem N, Kaslungka S, Luanratana O, Pongpan N, and Neungton N (2004) Antiproliferation, antioxidation and induction of apoptosis by Garcinia mangostana (mangosteen) on SKBR3 human breast cancer cell line. J Ethnopharmacol 90:161-166. (Pubitemid 38091702)
24. 2 synthesis by γ-mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. Biochem Pharmacol 63:73-79.
25. Nakatani K, Yamakuni T, Kondo N, Arakawa T, Oosawa K, Shimura S, Inoue H, and Ohizumi Y (2004) γ-Mangostin inhibits inhibitor-κB kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells. Mol Pharmacol 66:667-674. (Pubitemid 39329266)
26. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88-95.
27. Pouli N and Marakos P (2009) Fused xanthone derivatives as antiproliferative agents. Anticancer Agents Med Chem 9:77-98.
28. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448.
29. Ritchie MR (2007) Use of herbal supplements and nutritional supplements in the UK: what do we know about their pattern of usage? Proc Nutr Soc 66:479-482.
30. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-149. (Pubitemid 46745341)
31. Shakya G, Malla S, Shakya KN, and Shrestha R (2008) Therapeutic drug monitoring of antiepileptic drugs. J Nepal Med Assoc 47:94-97.
32. Si D, Wang Y, Zhou YH, Guo Y, Wang J, Zhou H, Li ZS, and Fawcett JP (2009) Mechanism of CYP2C9 inhibition by flavones and flavanols. Drug Metab Dispos 37:629-634.
33. Skalli S, Zaid A, and Soulaymani R (2007) Drug interactions with herbal medicines. Ther Drug Monit 29:679-686.
34. Tirona RG and Bailey DG (2006) Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 61:677-681.
35. Tucker GT, Houston JB, and Huang SM (2001) EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. European Federation of Pharmaceutical Sciences. Eur J Pharm Sci 13:417-428.
36. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660. (Pubitemid 38668158)
37. Yale SH and Glurich I (2005) Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 11:433-439.